Eversept Partners, LP
About Eversept Partners, LP’s 13F portfolio
Eversept Partners, LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Eversept Partners, LP reported $1.8B across 115 US-listed positions (). Its largest position is UNITED THERAPEUTICS CORP DEL (UTHR) at 8.5% of the reported book, and its ten biggest holdings make up 47% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: UTHR UNITED THERAPEUTICS CORP DEL | $577.34 −1.16% | 8.5% | 288K | $155.9M |
| 2 | NASDAQ: ABVX ABIVAX SA | $83.83 +2.11% | 6.6% | 914K | $121.8M |
| 3 | NYSE: EHC ENCOMPASS HEALTH CORP | $134.93 −2.14% | 5.7% | 1.0M | $103.8M |
| 4 | NASDAQ: ENSG ENSIGN GROUP INC | $182.98 −1.63% | 5.3% | 602K | $96.5M |
| 5 | NASDAQ: VERA VERA THERAPEUTICS INC | $25.58 −2.37% | 5.2% | 2.2M | $94.9M |
| 6 | NASDAQ: CLDX CELLDEX THERAPEUTICS INC NEW | $27.55 −1.75% | 3.6% | 1.8M | $66.5M |
| 7 | NASDAQ: SNDX SYNDAX PHARMACEUTICALS INC | $8.56 −6.96% | 3.3% | 2.8M | $61.2M |
| 8 | NYSE: BKD BROOKDALE SR LIVING INC | $8.59 −2.39% | 3.0% | 3.4M | $54.6M |
| 9 | NASDAQ: IONS IONIS PHARMACEUTICALS INC | $27.39 +1.59% | 2.9% | 665K | $52.7M |
| 10 | NASDAQ: NTRA NATERA INC | $289.50 +0.71% | 2.6% | 176K | $47.7M |
| 11 | NASDAQ: TVTX TRAVERE THERAPEUTICS INC | $50.24 −1.68% | 2.5% | 799K | $45.4M |
| 12 | NYSE: CTRE CARETRUST REIT INC | $37.95 +2.21% | 2.4% | 1.1M | $43.3M |
| 13 | NYSE: HCA HCA HEALTHCARE INC | $476.35 −4.96% | 2.1% | 98K | $38.3M |
| 14 | NASDAQ: PCVX VAXCYTE INC | $58.52 −1.48% | 2.0% | 630K | $36.6M |
| 15 | NASDAQ: LQDA LIQUIDIA CORPORATION | $56.40 −0.58% | 1.9% | 429K | $34.2M |
| 16 | NYSE: CYH COMMUNITY HEALTH SYS INC NEW | $1.86 −7.92% | 1.4% | 7.9M | $26.3M |
| 17 | NYSE: GSK GSK PLC | $48.58 −1.34% | 1.4% | 482K | $25.3M |
| 18 | NYSE: CHE CHEMED CORP NEW | $546.72 −0.01% | 1.3% | 53K | $24.5M |
| 19 | NYSE: LLY ELI LILLY & CO | $1,382.75 −2.32% | 1.3% | 20K | $24.1M |
| 20 | NASDAQ: GERN GERON CORP | $0.99 −0.91% | 1.3% | 18.7M | $24.0M |
| 21 | NASDAQ: VKTX VIKING THERAPEUTICS INC | $26.17 −2.64% | 1.3% | 603K | $23.5M |
| 22 | NYSE: OHI OMEGA HEALTHCARE INVS INC | $47.09 +0.66% | 1.3% | 484K | $23.1M |
| 23 | NASDAQ: PODD INSULET CORP | $139.98 −3.69% | 1.2% | 149K | $22.7M |
| 24 | NYSE: THC TENET HEALTHCARE CORP | $271.34 −3.80% | 1.2% | 114K | $21.4M |
| 25 | NYSE: UNH UNITEDHEALTH GROUP INC | $349.91 −10.21% | 1.2% | 51K | $21.3M |
Showing 1–25 of 115 positions on this page reported in this 13F.
- Healthcare93%
- Real Estate5.9%
- Financial Services0.0%
- AddedUTHRUNITED THERAPEUTICS CORP DEL+8.9%$155.9M
- AddedEHCENCOMPASS HEALTH CORP+429%$103.8M
- AddedENSGENSIGN GROUP INC+3979%$96.5M
- AddedVERAVERA THERAPEUTICS INC+1.8%$94.9M
- AddedIONSIONIS PHARMACEUTICALS INC+5.2%$52.7M
- AddedTVTXTRAVERE THERAPEUTICS INC+47.2%$45.4M
- NewCTRECARETRUST REIT INC—$43.3M
- AddedHCAHCA HEALTHCARE INC+24.0%$38.3M
- AddedCHECHEMED CORP NEW+69.1%$24.5M
- AddedLLYELI LILLY & CO+5.9%$24.1M
- ReducedABVXABIVAX SA−2.2%$121.8M
- ReducedCLDXCELLDEX THERAPEUTICS INC NEW−0.1%$66.5M
- ReducedSNDXSYNDAX PHARMACEUTICALS INC−3.0%$61.2M
- ReducedBKDBROOKDALE SR LIVING INC−4.8%$54.6M
- ReducedNTRANATERA INC−54.3%$47.7M
- ReducedPCVXVAXCYTE INC−31.8%$36.6M
- ReducedLQDALIQUIDIA CORPORATION−36.7%$34.2M
- ReducedCYHCOMMUNITY HEALTH SYS INC NEW−9.4%$26.3M
- ReducedGSKGSK PLC−73.0%$25.3M
- ReducedGERNGERON CORP−0.6%$24.0M
Reading Eversept Partners, LP’s 13F portfolio
Eversept Partners, LP’s $1.8B 13F book is spread across 115 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 47%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are UTHR, ABVX, EHC, ENSG and VERA, led by UNITED THERAPEUTICS CORP DEL (UTHR) at 8.5% of the portfolio. The heaviest sector exposure is Healthcare (93%), then Real Estate (6%).
What Eversept Partners, LP changed last quarter
Between 2026-03-31 and Q2 2026, Eversept Partners, LP was a net buyer: it opened 32 new positions and added to 37 more, while trimming 39 and closing 21 outright. Against a 115-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was UNITED THERAPEUTICS CORP DEL (UTHR), and its biggest reduction was ABIVAX SA (ABVX).
What a 13F does and doesn’t reveal
A 13F captures only Eversept Partners, LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Eversept Partners, LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Eversept Partners, LP's profile on this page is built directly from those filings.
How current is the 13F data on Eversept Partners, LP's page?
It reflects Eversept Partners, LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Eversept Partners, LP files its next quarterly report, this page refreshes automatically.
Can I see Eversept Partners, LP's complete list of holdings?
This page highlights Eversept Partners, LP's largest positions rather than all 115 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Eversept Partners, LP's filings.
Does a 13F show everything Eversept Partners, LP owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Eversept Partners, LP's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Eversept Partners, LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

